Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Hormone therapy drugs ‘increase heart disease risk’

December 10, 2010
Research and Development AstraZeneca, Hormone therapy, Novartis, Pfizer, aromatase inhibitors, breast cancer, tamoxifen

Three aromatase inhibitors could increase the risk of heart disease in postmenopausal women with breast cancer, according to new data. …

News

Novartis to cut 1,400 US sales jobs

December 2, 2010
Sales and Marketing Novartis, Novartis Pharma North America, Novartis Pharmaceuticals Corporation, job cuts, sales representatives

Novartis has outlined a major restructure of its US field force of sales reps that will see 1,400 positions cut …

News
Novartis’ Afinitor (everolimus)

Novartis fails to sway NICE with Afinitor deal

November 26, 2010
Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus

Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …

News
Age-related macular degeneration (Wet AMD)

Bayer’s challenger to Lucentis shows promise

November 22, 2010
Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD

Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …

News

Novartis outlines business strategy

November 18, 2010
Research and Development, Sales and Marketing Novartis, business development, pharma strategy

Novartis has outlined its long-term strategy for managing a number of key patent expiries. The Swiss-based pharma firm plans to …

News

Novartis drops late stage lung cancer candidate

November 11, 2010
Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer

Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …

News

Novartis signs Middle East vaccine production deal

November 9, 2010
Manufacturing and Production Agrippal, Arabio, Novartis, Quinvaxem, meningitis vaccine Menveo, vaccines

Novartis has forged an alliance with a Saudi Arabian manufacturer to help it expand its vaccines business in the Middle …

News

GCI bags Novartis’ social media director

November 8, 2010
Medical Communications GCI Health, Mark Davis, Novartis, appointment, medical communications

Novartis Pharmaceuticals’ former social media director Mark Davis has moved to GCI Health. He has been appointed to lead the …

Appointment

FDA approves Novartis’ Afinitor

November 1, 2010
Sales and Marketing Afinitor, Novartis, subependymal giant cell astrocytomas, tuberous sclerosis

Novartis’ drug Afinitor has been approved by US authorities as a first line treatment for patients with benign brain tumours …

News

Novartis’ Lucentis recommended for wider EU licence

October 25, 2010
Sales and Marketing CHMP, Genentech, Lucentis, Novartis, diabetic macular edema, ranibizumab

Novartis’ Lucentis has been recommended for approval in Europe to treat people suffering from vison loss due to diabetes. The …

News

Two thirds of pharma companies face ‘strategic crisis’

October 25, 2010
Research and Development, Sales and Marketing Novartis, Pfizer, Roland Berger, generics, pharma research, pharma sales

The pharma industry is moving away from traditional in-house innovation and toward a more diversified business model, but will encounter …

News

Novartis posts strong Q3 results

October 21, 2010
Sales and Marketing 2010 financials, Novartis, Novartis quarterly results, Q3, pharma sales

Novartis has posted double digit growth for the third quarter following a strong showing by a number of recently launched …

News

Cutting-edge cancer treatments showcased at ESMO

October 18, 2010
Research and Development AstraZeneca, Boehringer, Cancer, Cancer Conference, Johnson & Johnson, Novartis, personalised medicine

The search for a ‘silver bullet’ against cancer has failed, for now, with the battle against the disease turning instead …

Feature

Trial shows long-term benefits of Novartis’ Aclasta

October 18, 2010
Research and Development, Sales and Marketing Novartis, aclasta, osteoporosis

Novartis has published new data at the annual meeting of the American Society for Bone and Mineral Research in Toronto …

News

Novartis eyes genomics route for flu vaccines

October 11, 2010
Manufacturing and Production, Research and Development Novartis, Synthetic Genomics Vaccines, genomics

Novartis will make use of a technology developed by Synthetic Genomics Vaccines, a new company set up by genomics pioneer …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025